ArticleInternal medicine (Tokyo, Japan)2024
Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study.
Fumiya Kaneko et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.